The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Altered conformational landscape and dimerization dependency underpins the activation of EGFR by α C– β 4 loop insertion mutations
Abstract
Significance: The α C– β 4 loop is a conserved structural motif present in all eukaryotic protein kinases. This study focuses on epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that harbors many recurrent insertion mutations in the α C– β 4 loop. We show that EGFR activity and drug sensitivity are strongly dependent on the nature, size, and location of mutations in the loop and that even subtle variations in the loop have a dramatic effect on kinase dynamics and free-energy landscape. These findings inform ongoing drug-discovery efforts on EGFR kinases and provide a structural framework for investigating the role of the understudied α C– β 4 loop in kinase regulation, dynamics, and evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Not surprisingly somatic mutations in this highly conserved motif lead to cancer [31].”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [31]
In the citing paper
“The importance of αC-β4 loop is also reinforced because the cancer mutations are located here (Ruan and Kannan, 2018).”
From Protein Kinase Structure and Dynamics: Role of the αC-β4 Loop (2023) · cites this paper as Ruan and Kannan, 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 5×
“Structurally, the active state of the intracellular kinase domain is achieved through a “head-totail” configuration where one molecule of EGFR (the “donor” kinase) docks to the N lobe of another EGFR molecule (the “acceptor” kinase) in an asymmetric manner (9).”
BackgroundMethodInfluentialYun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610
Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571
Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase
Verba, K. A., Wang, R. Y.-R., Arakawa, A., Liu, Y., Shirouzu, M., Yokoyama, S., & Agard, D. A. (2016) · Science · doi:10.1126/science.aaf5023 · Cited by 424
Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211 · cited 1×
“Exon 20 insertions confer resistance to first-generation EGFR inhibitors and are associated with poor clinical outcomes (6, 18).”
BackgroundKohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210 · cited 2×
“Recent studies suggest that the drug response profile of exon 20 insertions is heterogeneous and depends on the nature of the inserted segment (15, 16, 19).”
BackgroundResultEGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131 · cited 2×
“Another recently published study showed that D770>GY is partially responsive to dacomitinib compared with other insertion mutations in the αC–β4 loop (16).”
BackgroundCho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1145 · Cited by 117 · cited 2×
“Consistent with our findings, a previous study focusing on the dimerization dependence of the D770 N771insNPG mutant found that the N-lobe dimerization-deficient mutation (L704N) had a more dramatic effect on the transforming activity of EGFR compared with the C-lobe dimerization-deficient mutation (I941R) (23).”
BackgroundResult
Research works printed but not linked: 52
- V Frattini, , The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45, 1141–1149 (2013). · DOI · Paper page
- KC Day, , Her2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res 77, 74–85 (2017). · DOI · Paper page
- H Masuda, , Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136, 331–345 (2012). · DOI · Paper page
- ME Arcila, , EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 12, 220–229 (2013). · DOI · Paper page
- DM Jackman, , Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12, 3908–3914 (2006). · DOI · Paper page
- CJ Tsai, R Nussinov, The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol 23, 235–242 (2013). · DOI
- Y Shan, , Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149, 860–870 (2012). · DOI · Paper page
- SA Foster, , Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell 29, 477–493 (2016). · DOI · Paper page
- JP Dawson, , Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell. Biol 25, 7734–7742 (2005). · DOI · Paper page
- Y Huang, , Molecular basis for multimerization in the activation of the epidermal growth factor receptor. Elife 5, e14107 (2016). · DOI · Paper page
- Z Wang, , Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol 18, 1388–1393 (2011). · DOI
- J Cho, , Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 13, 141 (2014). · DOI
- Z Ruan, N Kannan, Mechanistic insights into R776H mediated activation of epidermal growth factor receptor kinase. Biochemistry 54, 4216–4225 (2015). · DOI
- Z Ruan, S Katiyar, N Kannan, Computational and experimental characterization of patient derived mutations reveal an unusual mode of regulatory spine assembly and drug sensitivity in EGFR kinase. Biochemistry 56, 22–32 (2017). · DOI
- S Li, , Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301–311 (2005). · DOI · Paper page
- MD Fulton, , Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation. Bioorg Med Chem 26, 1167–1173 (2017). · DOI
- Y Shan, A Arkhipov, ET Kim, AC Pan, DE Shaw, Transitions to catalytically inactive conformations in EGFR kinase. Proc Natl Acad Sci USA 110, 7270–7275 (2013). · DOI · Paper page
- KA White, , Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins. Sci Signal 10, eaam9931 (2017). · DOI
- DD Wang, W Zhou, H Yan, M Wong, V Lee, Personalized prediction of EGFR mutation-induced drug resistance in lung cancer. Sci Rep 3, 2855 (2013). · DOI
- L Ma, , EGFR mutant structural database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib. BMC Bioinformatics 16, 85 (2015). · DOI
- S Kannan, , Hydration effects on the efficacy of the epidermal growth factor receptor kinase inhibitor afatinib. Sci Rep 7, 1540 (2017). · DOI
- Y Li, X Li, W Ma, Z Dong, Conformational transition pathways of epidermal growth factor receptor kinase domain from multiple molecular dynamics simulations and Bayesian clustering. J Chem Theor Comput 10, 3503–3511 (2014). · DOI
- AC Pan, TM Weinreich, Y Shan, DP Scarpazza, DE Shaw, Assessing the accuracy of two enhanced sampling methods using EGFR kinase transition pathways: The influence of collective variable choice. J Chem Theor Comput 10, 2860–2865 (2014). · DOI
- L Sutto, FL Gervasio, Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci USA 110, 10616–10621 (2013). · DOI · Paper page
- H Chen, , A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell. 27, 717–730 (2007). · DOI · Paper page
- T Klein, , Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nat Commu 6, 7877 (2015). · DOI
- N Kannan, AF Neuwald, Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol 351, 956–972 (2005). · DOI · Paper page
- W Xu, , Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol 12, 120–126 (2005). · DOI
- JT den Dunnen, SE Antonarakis, Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat 15, 7–12 (2000). · DOI · Paper page
- DI McSkimming, , Prokino: A unified resource for mining the cancer kinome. Hum Mutat 36, 175–186 (2015). · DOI
- K Politi, TJ Lynch, Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Clin Cancer Res 18, 1490–1492 (2012). · DOI
- M Red Brewer, , Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci USA 110, E3595–E3604 (2013). · DOI
- N Minkovsky, A Berezov, BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 9, 1336–1346 (2008).
- Y Yosaatmadja, , Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J Struct Biol 192, 539–544 (2015). · DOI
- DI McSkimming, K Rasheed, N Kannan, Classifying kinase conformations using a machine learning approach. BMC Bioinformatics 18, 86 (2017). · DOI
- Y Kawakita, , Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorg Med Chem 21, 2250–2261 (2013). · DOI
- E Sajnaga, K Kubiński, R Szyszka, Catalytic activity of mutants of yeast protein kinase CK2alpha. Acta Biochim Pol 55, 767–776 (2008). · doi:10.18388/abp.2008_3039
- ED Scheeff, J Eswaran, G Bunkoczi, S Knapp, G Manning, Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17, 128–138 (2009). · DOI · Paper page
- JCK Ngo, , SR protein kinase 1 is resilient to inactivation. Structure 15, 123–133 (2007). · DOI
- S Meinhardt, MWJ Manley, DJ Parente, L Swint-Kruse, Rheostats and toggle switches for modulating protein function. PLoS One 8, e83502 (2013). · DOI
- W Xu, , Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br J Cancer 97, 741–744 (2007). · DOI
- N Eswar, , Comparative protein structure modeling using modeller. Curr Protoc Bioinformatics Chapter 5, Unit-U5.6 (2006).
- DJ Mandell, EA Coutsias, T Kortemme, Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational sampling. Nat Methods 6, 551–552 (2009). · DOI · Paper page
- MJ Abraham, , Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19–25 (2015). · DOI · Paper page
- M Bonomi, , Plumed: A portable plugin for free-energy calculations with molecular dynamics. Comput Phys Commun 180, 1961–1972 (2009). · DOI · Paper page
- K Lindorff-Larsen, , Improved side-chain torsion potentials for the Amber ff99sB protein force field. Proteins 78, 1950–1958 (2010). · DOI · Paper page
- S Páll, B Hess, A flexible algorithm for calculating pair interactions on SIMD architectures. Comput Phys Commun 184, 2641–2650 (2013). · DOI · Paper page
- G Bussi, D Donadio, M Parrinello, Canonical sampling through velocity rescaling. J Chem Phys 126, 014101 (2007). · DOI · Paper page
- HJC Berendsen, JPM Postma, G WFv, A DiNola, JR Haak, Molecular dynamics with coupling to an external bath. J Chem Phys 81, 3684–3690 (1984). · DOI · Paper page
- S Kumar, D Bouzida, RH Swendsen, PA Kollman, JM Rosenberg, The weighted histogram analysis method for free-energy calculations on biomolecules. I. The method. J Comput Chem 13, 1011–1021 (1992). · DOI · Paper page
- MK Scherer, , PyEMMA 2: A software package for estimation, validation, and analysis of Markov models. J Chem Theor Comput 11, 5525–5542 (2015). · DOI · Paper page
- B Ensing, A Laio, M Parrinello, ML Klein, A recipe for the computation of the free energy barrier and the lowest free energy path of concerted reactions. J Phys Chem B 109, 6676–6687 (2005). · DOI · Paper page
Cited by
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Del Re, M., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 356
Brown, B. P., Stein, R. A., Meiler, J., & Mchaourab, H. S. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c01081 · Cited by 41
Olivieri, C., Wang, Y., Walker, C., Subrahmanian, M. V., Ha, K. N., Bernlohr, D., Gao, J., Camilloni, C., Vendruscolo, M., Taylor, S. S., et al. (2024) · eLife · doi:10.7554/elife.91506.3 · Cited by 18
Protein Kinase Structure and Dynamics: Role of the αC-β4 Loop
Wu, J., Jonniya, N. A., Hirakis, S. P., Olivieri, C., Veglia, G., Kornev, A. P., & Taylor, S. S. (2023) · doi:10.1101/2023.08.31.555822 · Cited by 17
Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development
Olivieri, C., Wu, J., Taylor, S. S., & Veglia, G. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103169 · Cited by 1
Metadata
- Authors
- Ruan, Z., & Kannan, N.
- Affiliations
- Institute of Bioinformatics, University of Georgia, Athens, GA 30602;
- ORCID
- Ruan, Zheng
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-08-13
- Volume
- 115
- Issue
- 35
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 65
- References
- 15
- Language
- en
- Funders
- HHS | National Institutes of Health (5RO1GM114409)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.